Category
research
Close reads of the primary literature — trial data, effect sizes, and what the studies can and cannot yet tell us.
research
GLP-1 Combinations: What Asian T2D Data Show
Ian Gauntt, RN BSN · Sep 18, 2026 · 12 min
A 2025 review examines GLP-1 combinations with basal insulin in Asian adults with type 2 diabetes—what the data show on efficacy, safety, and dosing.
research
Tirzepatide: What Sleep Apnea Research Shows
Ian Gauntt, RN BSN · Sep 11, 2026 · 13 min
New post-hoc analyses of SURMOUNT-OSA examine tirzepatide and sleep apnea outcomes by baseline characteristics. Here is what the clinical data actually found.
research
Gene‑encoded micropeptides as actionable targets
Ian Gauntt, RN BSN · Sep 9, 2026 · 2 min
Review uncovers gene‑encoded micropeptides from sORFs in lncRNAs, circRNAs and UTRs as functional regulators and emerging therapeutic targets in cancer and immunity
research
Tirzepatide: Blood Pressure and Cardiometabolic Data
Ian Gauntt, RN BSN · Aug 28, 2026 · 13 min
New meta-analyses examine tirzepatide blood pressure, weight, and cardiovascular risk markers. Here's what the studies found.
research
Romiplostim: What Research Shows
Ian Gauntt, RN BSN · Aug 21, 2026 · 14 min
Romiplostim research in immune thrombocytopenia: what a 2025 systematic review and meta-analysis found about efficacy and safety signals.
research
New Peptides: What Research Shows
Ian Gauntt, RN BSN · Aug 14, 2026 · 13 min
New peptides are reshaping research in 2025. Explore what clinical studies show about LTI-03, zenagamtide, eptinezumab, and more.
research
Semaglutide & Liver Disease: What Studies Show
Ian Gauntt, RN BSN · Aug 7, 2026 · 12 min
New meta-analysis data on semaglutide and metabolic liver disease explained. What placebo-controlled trials found—and what remains unknown.
research
Semaglutide: What Research Shows
Ian Gauntt, RN BSN · Jul 31, 2026 · 12 min
What does recent research say about semaglutide? Explore findings on fatty liver, diabetes prevention, and PCOS from clinical and meta-analysis studies.
research
Retatrutide: What the Trials Actually Show
Ian Gauntt, RN BSN · Jul 5, 2026 · 2 min
The triple-agonist everyone's whispering about has real, published human RCTs behind it — up to 24.2% weight loss at 48 weeks and dramatic liver-fat drops. Here's what the data say, and what it still can't tell you.